23 closest matches · ranked by relevance
Graves Disease
Primary: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities up to Week 22 Compared to Baseline. — 311; 293; 18; 0…
Thyroid-associated Ophthalmopathy
Primary: Change in Clinical Activity Score (CAS) — -1.2; -1.5 units on a scale — p=0.73
Graves' Disease
Primary: Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize After 12 Week Treatment — 0 percentage of participants
Graves Ophthalmopathy
Primary: Percent Change Lumbar Spine Bone Mineral Density — 1.37 Percentage change
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Graves' Disease
Primary: Dosimetry Studies
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48
Thyroid Eye Disease · Graves' Orbitopathy
Primary: Percentage of Participants Who Were Proptosis Responders at Week 24 — 9.5; 82.9 percentage of participants — p=<0.001
Ophthalmopathy, Thyroid-Associated
Primary: Clinical Activity Score (a Composite Measure of Ophthalmological Signs and Symptoms) — 4.25; 2.77; 4.25; 4.20 score on a scale
Graves' Ophthalmopathy
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment…
Graves Disease · Hyperthyroidism
Primary: Blood Loss During Surgery — 61.67; 161.67 mL
Thyroid Eye Disease
Primary: Percentage of Participants With a ≥ 2 mm Reduction From Baseline in the Study Eye Without Deterioration of Proptosis in the Fellow Eye at Week 24 — 89.2; 53.8 percentage…
Thyroid Diseases
Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale
Thyroid Eye Disease
Primary: Change in IOP Before and After Orbital Decompression Surgery — 18 mVEq (Sensismed Triggerfish output unit)
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
Thyroid Associated Ophthalmopathies · Thyroid-Associated Ophthalmopathy
Primary: Responder Status at Week 24 — 9; 29; 36; 13 Participants — p=< 0.001
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
Thyroid Cancer
Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
Subclinical Hypothyroidism
Primary: TSH Area Under the Curve — 267.8; 266.2 μIU*min/mL
Vitamin B12 Deficiency
Primary: Prevalence of Vitamin B12 Deficiency — 3; 6; 4 participants